What Stediril 30 Treats: Main Uses and Benefits

The therapeutic application of this combined hormonal medication is relevant for easing multiple symptoms related to systemic imbalance, extending beyond its primary function. Its use may assist with addressing symptoms that interfere with daily functioning.

Primary Benefit: Contributes to Effective Contraception

This medication's essential purpose is commonly used to help with pregnancy prevention for women of reproductive potential. Consistent, structured use of this combined oral contraceptive offers a foundational benefit, which supports effective family planning and reproductive timing.

Quick Fact: Relief for Painful Symptoms The use of this medication may assist with easing the symptom load related to severe menstrual cramping (dysmenorrhea).

Management of Cyclical and Hormonal Symptoms

Stediril 30 is applied in clinical contexts to manage challenging menstrual symptoms. The formulation is applied to address issues of irregular and unpredictable cycle timing, and is commonly used to help with a sense of predictable cycle management. It plays a role in managing conditions presenting with symptoms of excessive blood loss (menorrhagia), hormonal acne, and severe cyclical mood changes related to PMDD. By addressing symptoms that interfere with daily comfort, it may assist with promoting functional stability. The use of this medication may assist with controlling bleeding severity, which contributes to easing the resulting noticeable physiological strain of the menstrual period. Additionally, its use generally supports a sense of stability when symptoms are more noticeable and contributes to easing discomfort.

Who Can and Cannot Use Stediril 30?

Eligibility for Stediril 30, a combined oral contraceptive (COC), is strictly defined by regulatory bodies to manage specific health risks associated with the hormonal components (Ethinyl Estradiol and Levonorgestrel).

Populations Allowed

Use is officially indicated for females of reproductive potential and is restricted to individuals who have reached menarche (onset of menstruation).

Absolute Contraindications (Must Not Use)

Condition Category	Examples of Non-Eligible Populations
Thrombotic Risk	History of blood clots (VTE or ATE), including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, or Myocardial Infarction.
Vascular Disease	Women over 35 who smoke, severe hypertension, or diabetes with vascular symptoms.
Hormone-Sensitive	Current or history of breast cancer or other known sex-steroid influenced malignancies.
Hepatic Function	Severe liver disease, history of liver tumours, or use with certain Hepatitis C drug combinations.

Age and Physiological Status Rules

Stediril 30 is contraindicated if pregnancy is present or suspected. It is not indicated for use in post-menopausal women. Furthermore, use must be discontinued at least four weeks before and two weeks after any major surgery associated with prolonged immobilization.

Interactions with other medicines and products

Official regulatory information describes interactions for the active ingredients Ethinyl Estradiol and Levonorgestrel, primarily involving changes in plasma exposure due to metabolic enzyme activity.

---

Documented Interaction Categories

Classification Property	Official Regulatory Definition
Interaction Severity	Contraindicated Combinations; Clinically Significant Interactions
Mechanistic Basis	Hepatic Enzyme Induction/Inhibition ( CYP3 A4); Glucuronidation Alteration

---

Official Interaction Statements

• Co-administration with specific Hepatitis C drug regimens, such as those containing Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir, is formally prohibited due to the risk of significant Alanine Transaminase ( ALT) enzyme elevations.
• The concurrent use of hepatic enzyme-inducing medicines, including certain anticonvulsants (e.g., Carbamazepine, Phenytoin) and the herbal product St John's wort, results in decreased plasma concentrations and reduced clearance of the hormonal components.
• Conversely, co-administration with CYP3 A4 inhibiting medicines or substances like Grapefruit Juice may increase the total plasma exposure of the hormonal components.
• Combined oral contraceptives are documented to decrease the plasma concentrations of certain co-administered drugs, such as Lamotrigine, by accelerating their metabolism.
• Following the discontinuation of an enzyme-inducing medicine, a non-hormonal contraceptive method must be used for a mandatory period of 28 days, as stated in regulatory documents.

Stediril 30 functions as a combined hormonal contraceptive, containing the synthetic estrogen ethinylestradiol and the synthetic progestin levonorgestrel.

Levonorgestrel acts as an agonist at the progesterone receptor and androgen receptor in target tissues, including the hypothalamus, pituitary gland, and reproductive organs. This agonism exerts a negative feedback signal on the hypothalamic-pituitary-ovarian (HPO) axis, leading to the suppression of gonadotropin-releasing hormone (GnRH) pulse frequency from the hypothalamus. This, in turn, reduces the secretion of pituitary luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

The suppression of these gonadotropins prevents the mid-cycle LH surge, thereby inhibiting follicular development and ovulation from the ovaries. Levonorgestrel also induces changes in the cervical mucosa, resulting in thickened cervical mucus that impedes sperm migration into the upper reproductive tract. Ethinylestradiol serves to potentiate the suppression of FSH secretion, contributing to the overall inhibition of the HPO axis and the stability of the endometrium.

Official Administration Guidelines for Stediril 30

Stediril 30 is a monophasic Combined Oral Contraceptive (COC) containing 0.15 mg Levonorgestrel and 0.03 mg Ethinyl Estradiol in each active tablet. Its use is governed by a strict daily and cyclic administration pattern, as outlined in standard prescribing information for females of reproductive potential.

---

Core Usage Structure

Feature	Official Instruction
Route of Administration	The medication is for Oral use, taken by swallowing the tablet.
Dosing Schedule	One tablet daily. The standard regimen involves 21 consecutive days of active tablets followed by 7 days of inactive (placebo) tablets or a hormone-free interval.
Daily Timing	The tablet must be taken once daily at approximately the same time every day to maintain a consistent hormonal exposure.
Food Intake	The tablets may be taken with or without food

---

Procedural Use Constraints

Administration for a new cycle can begin using either a Day 1 Start (first day of menses) or a Sunday Start (first Sunday after menses onset). To ensure adherence to the labeled use, the tablet-taking interval must never exceed 24 hours, and the hormone-free interval must not be extended beyond 7 days.

Standard instructions provide specific steps for managing missed doses. For instance, if a single active tablet is missed, it should be taken immediately upon remembrance, even if that results in taking two tablets on the same day. These structured rules for use and adherence are essential to follow the defined administration protocol.

Research evidence / Overview of Studies for Stediril 30

---

Evidence for Use in Pregnancy Prevention (Contraception)

This section will summarize the structure of the official research base, including the Randomized Controlled Trials and Systematic Reviews that examined the method's intended use and documented the primary outcome of pregnancy rates in healthy women. Research explored outcomes related to systemic or functional imbalance (ovulation) in healthy women of reproductive age. Studies monitored the resulting pregnancy rates over defined time intervals. Trials measured patterns consistent with a low occurrence of pregnancy among participants. Additionally, research describes the observed phenomenon of ovarian activity suppression. The evidence is described through systematic reviews and meta-analyses.

Evidence for Management of Menstrual Symptoms

This part will outline the studies, such as Randomized Trials, that examined this formulation in clinical situations such as excessive menstrual blood loss (menorrhagia) and the severity of menstrual cramping (dysmenorrhea). Research examined these uses in Randomized Controlled Trials applied in studies examining patient-reported experiences. For excessive blood loss, studies monitored outcomes related to physical discomfort and reported measurements of a lower volume of menstrual blood loss after several cycles of observation.

Research on Cycle Regularity and Pain

Trials reported how symptoms evolved in the observed populations, noting decreases in the recorded severity of menstrual pain. The data provide information on patterns consistent with a reduced frequency of using supplemental pain medication. However, follow-up durations were limited for long-term tracking, and data for certain groups remain insufficient, specifically for women whose cramping is due to an underlying condition.

---

Evidence for Use in Hormonal Acne

Research explored this application in Randomized, Double-Blind, Placebo-Controlled Trials involving female subjects with moderate facial acne. Studies monitored outcomes linked to inflammatory or irritative states using lesion counts and investigator assessments. Research highlights changes measured during the study period, where trials reported measured outcomes related to lower inflammatory and total acne lesion counts. Long-term effects are not fully established beyond the typical six-month trial period used in research exploring short-term symptom changes.

---

What is Still Uncertain About the Research Base

This final part highlights areas where the current research base has limitations. The evidence quality varies across studies, and many trials utilized sample sizes that were modest. Overall, research provides context but not individual predictions, and the evidence is limited regarding the full extent of individual variability in response. The specific study results reflect the conditions under which they were conducted and cannot predict whether an individual will respond similarly.

Common questions about Stediril 30 (FAQ)

---

Q: What should I do if I miss a pill?

A: Official regulatory documents provide a specific set of rules for managing a missed dose. The specific actions outlined in the product information depend on the number of tablets missed, the time elapsed since the dose was due, and the week of the cycle. It is important to refer to the prescribing information for the detailed steps to help maintain the method's contraceptive efficacy.

---

Q: Can I use Stediril 30 for acne?

A: Combined oral contraceptives, which share the same hormonal ingredients as Stediril 30, are primarily indicated for the prevention of pregnancy. Some combined oral contraceptives containing these ingredients are formally indicated for the treatment of moderate acne, for women who also desire contraception.

---

Q: Can I take Stediril 30 if I have a history of migraines?

A: Official product information states that this medication is contraindicated (should not be used) in the presence of migraine with focal neurological symptoms. Furthermore, combined oral contraceptives are generally not advised for women over the age of 35 who smoke and have any type of migraine.

---

Q: How soon after stopping Stediril 30 can I get pregnant?

A: Studies and official information indicate that the return to normal fertility after discontinuing combined oral contraceptives is not delayed. Most women who stop using this method will typically have a rate of conception similar to those who previously used non-hormonal birth control methods.

---

Q: Does Stediril 30 offer protection against STIs?

A: No. Official safety warnings clearly state that combined oral contraceptives, including Stediril 30, do not protect against Human Immunodeficiency Virus (HIV/AIDS) or any other sexually transmitted infections (STIs).

---

Q: Is it safe to breastfeed while taking Stediril 30?

A: Regulatory documents generally advise against the use of estrogen-containing combined oral contraceptives, like Stediril 30, by mothers who are nursing. These hormones may affect the quantity and quality of breast milk and are generally not advised during the immediate postpartum period, according to regulatory documents.

---

Q: What should I do if I vomit after taking the pill?

A: According to the official product information, if vomiting occurs within a short window (typically stated as 3 to 4 hours) of taking an active tablet, the absorption of the hormones may be incomplete. Official product information states that a replacement active tablet should be taken immediately and the missed dose instructions should then be followed.

---

Q: How quickly does Stediril 30 start working for birth control?

A: If the medication is started on the very first day of the menstrual cycle (Day 1 Start), contraceptive protection is considered established immediately. If it is started on any other day, regulatory documents indicate that a non-hormonal back-up method must be used for the first seven consecutive days of taking the active tablets.

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of this medication, which contains the active ingredients levonorgestrel and ethinylestradiol.

Requirement Type	Official Regulatory Statement
Temperature Control	Store below 30°C.
Environmental Protection	Store in the original package to protect from moisture and direct sunlight.
Disposal Instructions	Dispose of any unused product or waste material in accordance with local requirements.

These official statements specify that the product must be kept in a cool, protected environment below 30°C and shielded from light and moisture to maintain its labeled quality. For disposal, the mandatory instruction is to follow local waste management protocols for unused medicines.